Abstract:Bader B Alsulays, Alhussain H Aodah, Mohammad Muqtader Ahmed, Md Khalid Anwer Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia Correspondence: Bader B Alsulays, Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj, Saudi Arabia, Tel +966-554112830, Email Purpose: Ivosidenib (IVO), an isocitrate dehydrogenase-1 (IDH1) used for treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. However, poor solubility, low bioavailability, high dose and side effects limit clinical application of IVO. Methods: Ivosidenib-loaded PLGA nanoparticles (IVO-PLGA-NPs) and Ivosidenib-loaded chitosan coated PLGA nanoparticles (IVO-CS-PLGA-NPs) were prepared using emulsification and solvent evaporation method for the treatment of liver cancer. Results: The developed IVO-PLGA-NPs were evaluated for their particle size (171.7± 4.9 nm), PDI (0.333), ZP (− 23.0± 5.8 mV), EE (96.3± 4.3%), and DL (9.66± 1.1%); similarly, the IVO-CS-PLGA-NPs were evaluated for their particle size (177.3± 5.2 nm), PDI (0.311), ZP +25.9± 5.7 mV, EE (90.8± 5.7%), and DL (9.42± 0.7%). The chitosan coating of IVO-PLGA-NPs was evidenced by an increase in mean particle size and positive ZP value. Because of the chitosan coating, the IVO-CS-PLGA-NPs showed a more stable and prolonged release of IVO than IVO-PLGA-NPs. In comparison to pure-IVO, the IVO-PLGA-NPs and IVO-CS-PLGA-NPs were found to be more effective against HepG2 cells, with IC 50 values for the MTT assay being approximately half of those of pure-IVO. In HepG2 cells, the expressions of caspase-3, caspase-9, and p53 were significantly (p < 0.05) elevated. Conclusion: Overall, these findings suggest that chitosan coating of IVO-PLGA-NPs improves the delivery and efficacy of ivosidenib in liver cancer treatment. Keywords: polymers, characterization, bioavailability, sustained release, caspase Liver cancer is one of the most common cancers globally, and one of the highest cause of the cancers related death. Most of the liver cancer cases were in the form of Hepatocellular carcinoma (HCC). Lack of effective treatment is the main reason of high mortality rate. The classical chemotherapy is insufficient and there is a significant chemoresistance of HCCs. 1–3 Ivosidenib, is a newly FDA approved drug for the treatment of adults with relapsed or refractory acute myeloid leukemia. It is an inhibitor of mutated cytosolic isocitrate dehydrogenase 1 (IDH1). Cholangiocarcinoma, solid tumor and other tumors are other indications of Ivosidenib, which are now undergoing clinical development worldwide. 4–6 It is classified as BCS class II drug with poor solubility and high permeability. 7 The poor aqueous solubility will further affect the bioavailability of the drug and limit its clinical effect. In order to improve the solubility of poorly soluble drug, many techniques, such as solid dispersion, salt formation, complexation, and nanoparticle were employed. Among these techniques, nanoparticle has gained considerable attention and extensively investigated in the pharmaceutical industry. Due to its advantages in improving drug solubility, bioavailability, stability and high encapsulation efficiency, polymeric nanoparticles were frequently used in drug development. 8,9 Nanostructures offer a promising solution to the challenges faced in the treatment of liver cancer, particularly in combating drug resistance. The ability of nanostructures to deliver drugs directly to cancer cells can help overcome issues such as limited drug penetration and efficacy, as well as reduce systemic toxicity. 10 Biodegradable polymers which used in polymeric nanoparticle formulation have some benefits of being less toxic and its role in improving the physiochemical properties of poorly soluble drugs. PLGA, short for poly(lactic-co-glycolic acid), is a remarkable polymer that has gained considerable recognition in the realm of biomedical research and pharmaceutical development. It is US-FDA approved copolymer, making it a highly trusted choice for the preparation of various polymeric nanoparticle-based formulations. Many applications of this polymer including enhancing the solubility, bioavailability, and stability have been reported. PLGA polymers play a crucial role in delivering anticancer drugs directly to tumor sites, maximizing treatment efficacy while minimizing side effects. The ability of PLGA to encapsulate and release drugs in a controlled manner enhances the therapeutic outcomes of cancer treatments. 11,12 Although, many advantages of PLGA NPs, it impart negative surface potential, which decrease the mucoadhesive properties as well as -Abstract Truncated-

Application of PLGA-ion exchange resin microcapsules of sulfasalazine â€Žfor embolization therapy

Preparation and Characterization of Irinotecan Loaded Cross-Linked Bovine Serum Albumin Beads for Liver Cancer Chemoembolization Therapy

Development, Optimization, and in vitro Evaluation of Silybin-loaded PLGA Nanoparticles and Decoration with 5TR1 Aptamer for Targeted Delivery to Colorectal Cancer Cells

Studies on Alginate-Chitosan Microcapsules and Renal Arterial Embolization in Rabbits.

Encapsulation and Controlled Release of Resveratrol Within Functionalized Mesoporous Silica Nanoparticles for Prostate Cancer Therapy

Biodegradable poly(lactide-co-glycolide) microspheres encapsulating hydrophobic contrast agents for transarterial chemoembolization

Alginate sulfonamide hydrogel beads for 5-fluorouracil delivery: antitumor activity, cytotoxicity assessment, and theoretical investigation

Using PVA and TPGS as combined emulsifier in nanoprecipitation method improves characteristics and anticancer activity of ibuprofen loaded PLGA nanoparticles

PLGA and PDMS-based in situ forming implants loaded with rosuvastatin and copper-selenium nanoparticles: a promising dual-effect formulation with augmented antimicrobial and cytotoxic activity in breast cancer cells

Biodegradable Microembolics with Nanografted Polyanions Enable High-Efficiency Drug Loading and Sustained Deep-Tumor Drug Penetration for Locoregional Chemoembolization Treatment

Study on the preparation and activity of intelligent response poly(lactic-co-glycolic acid)-ss-polyethylene glycol copolymer micelles

PLGA-graphene quantum dot nanocomposites targeted against αvβ3 integrin receptor for sorafenib delivery in angiogenesis

Engineered PLGA Core-Lipid Shell Hybrid Nanocarriers Improve the Efficacy and Safety of Irinotecan to Combat Colon Cancer

Improving the targeting and therapeutic efficacy of anastrazole for the control of breast cancer: In vitro and in vivo characterization

Preparation and Evaluation of Chitosan Coated PLGA Nanoparticles Encapsulating Ivosidenib with Enhanced Cytotoxicity Against Human Liver Cancer Cells

Preparation and Evaluation of Biocompatible Long-Term Radiopaque Microspheres Based on Polyvinyl Alcohol and Lipiodol for Embolization

Research of novel biocompatible radiopaque microcapsules for arterial embolization

Formulation and development of novel Sulfasalazine bilayer tablets for the treatment of arthritis associated with IBD: In-vitro and In-vivo Investigations

Fabrication of ibuprofen/naringenin-coloaded into zein/sodium caseinate nanoparticles: evaluation of antiproliferative activity and apoptosis induction in liver cancer cells

Exemestane encapsulated polymer-lipid hybrid nanoparticles for improved efficacy against breast cancer: optimization, in vitro characterization and cell culture studies

Preparation of chelidonine highly loaded poly(lactide-co-glycolide)-based nanoparticles using a single emulsion method: Cytotoxic effect on MDA-MB-231 cell line